Abstract:As the most important intestinal mucosal barrier of the main body, the innate immune barrier in intestinal tract plays especially pivotal roles in the overall health conditions of infants and young children; therefore, how to strengthen the innate immune barrier is pivotal. A variety of bioactivities of lactoferrin (LF) has been widely proved, including alleviating enteritis and inhibiting colon cancer; however, the effects of LF on intestinal immune barrier in infants and young children are still unclear, and the specific mechanism on how LF inhibits infantile enteritis by regulating immune signaling pathways is unrevealed. In the present study, we firstly performed pharmacokinetic analyses of LF in mice intestinal tissues, stomach tissues and blood, through different administration methods, to confirm the metabolic method of LF in mammals. Then we constructed in Vitro and in Vivo infantile intestinal immune barrier damage models utilizing lipopolysaccharide (LPS), and evaluated the effects of LF in alleviating LPS-induced intestinal immune barrier damage. Next, the related immune molecular mechanism on how LF exerted protective effects was investigated, through RNA-seq analyses of the mouse primary intestinal epithelial cells, and the specific genes were analyzed and screened out. Finally, the genes and their related immune pathway were validated in mRNA and protein levels; the portions of special immune cells (CD4+ T cells and CD8+ T cells) were also detected to further support our experimental results. Pharmacokinetic analyses demonstrated that the integrity of LF could reach mice stomach and intestine after oral gavage within 12 h, and the proper administration of LF should be the oral route. LF was proven to down-regulate the expression levels of inflammatory cytokines in both the primary intestinal epithelial cells and mice blood, especially LF without iron (Apo-LF), indicating LF alleviated infantile intestinal immune barrier damage induced by LPS. And through RNA-seq analyses of the mouse primary intestinal epithelial cells treated with LPS and LF, embryonic lethal abnormal vision Drosophila 1 (ELAVL1) was selected as one of the key genes, then the ELAVL1/PI3K/NF-κB pathway regulated by LF was verified to participate in the protection of infantile intestinal immune barrier damage in our study. Additionally, the ratio of blood CD4+/CD8+ T cells was significantly higher in the LF-treated mice than in the control mice, indicating that LF distinctly reinforced the overall immunity of infantile mice, further validating the strengthening bioactivity of LF on infantile intestinal immune barrier. In summary, LF was proven to alleviate LPS-induced intestinal immune barrier damage in young mice through regulating ELAVL1-related immune signaling pathways, which would expand current knowledge of the functions of bioactive proteins in foods within different research layers, as well as benefit preclinical and clinical researches in a long run.

Immunoregulation of bovine lactoferrin together with osteopontin promotes immune system development and maturation

Supplementation Transgenic Cow’s Milk Containing Recombinant Human Lactoferrin Enhances Systematic and Intestinal Immune Responses in Piglets

Benefits of Lactoferrin, Osteopontin and Milk Fat Globule Membranes for Infants

The application of lactoferrin in infant formula: The past, present and future

Sex-Dependent Modulation Of Immune Development In Mice By Secretory Iga-Coated Lactobacillus Reuteri Isolated From Breast Milk

Lactoferrin, a Critical Player in Neonate Intestinal Development: RHLF May Be a Good Choice in Formula

The impact of complexation or complex coacervation of lactoferrin and osteopontin on simulated infant gastrointestinal digestion, intestinal inflammation, and in vivo bone development

The Bovine Lactoferrin-Osteopontin Complex Increases Proliferation of Human Intestinal Epithelial Cells by Activating the PI3K/Akt Signaling Pathway.

Effect of dietary lactoferrin on the immune functions and serum iron level of weanling piglets.

A Literature Review on Lactopontin and Its Roles in Early Life

Lactoferrin Alleviates Lipopolysaccharide-Induced Infantile Intestinal Immune Barrier Damage by Regulating an ELAVL1-Related Signaling Pathway

Effects of Lactococcus lactis MG1363 producing fusion proteins of bovine lactoferricin–lactoferrampin on growth, intestinal morphology and immune function in weaned piglet

Effects of Forming Lactoferrin–Milk Protein Complexes on Lactoferrin Functionality and Intestinal Development in Infancy

Osteopontin in human milk and infant formula affects infant plasma osteopontin concentrations

Gastro-Intestinal Digested Bovine Milk Osteopontin Modulates Gut Barrier Biomarkers In Vitro

Effects of dietary supplementation of bovine lactoferrin on growth performance, immune function and intestinal health in weaning piglets

Lactoferrin preserves bone homeostasis by regulating the RANKL/RANK/OPG pathway of osteoimmunology.

Early-life lactoferrin intervention modulates the colonic microbiota, colonic microbial metabolites and intestinal function in suckling piglets

Optimum Fermentation Conditions for Bovine Lactoferricin-Lactoferrampin-Encoding LimosiLactobacillus reuteri and Regulation of Intestinal Inflammation

The Impact of Lactoferrin on the Growth of Intestinal Inhabitant Bacteria

Lactoferrin Supplementation during Gestation and Lactation Is Efficient for Boosting Rat Pup Development